Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Expert Rev Anticancer Ther. 2024 Mar 18:1-19. doi: 10.1080/14737140.2024.2330601. Online ahead of print.ABSTRACTINTRODUCTION: Chemotherapy has been traditionally used as neo-adjuvant therapy in breast cancer for down-staging of locally advanced disease in all sub-types. In the adjuvant setting, genomic assays have shown that a significant proportion of ER positive/HER2 negative patients do not derive benefit from the addition of chemotherapy to adjuvant endocrine therapy. An interest in hormonal treatments as neo-adjuvant therapies in ER positive/HER2 negative cancers has been borne by their documented success in the adjuv...
Source: Expert Review of Anticancer Therapy - March 13, 2024 Category: Cancer & Oncology Authors: Athina Stravodimou Ioannis A Voutsadakis Source Type: research
Ovarian Suppression: Early Menopause and Late Effects
Opinion statementAround 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine therapy, tailored according to disease stage, biological characteristics of the tumour, patient ’s comorbidities, preferences and age. In premenopausal patients with hormone receptor-positive breast cancer, ovarian function suppression is a key component of the adjuvant endocrine treatment in combination with an aromatase inhibitor or tamoxifen. Moreover, it can be used during chemoth...
Source: Current Treatment Options in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Chemotherapy combined with endocrine neoadjuvant therapy for hormone receptor-positive local advanced breast cancer: a case report and literature review
ConclusionsA novel approach involving concurrent neoadjuvant therapy with CT and endocrine therapy may offer a potentially effective treatment avenue for some cases with HR+ LABC. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - March 13, 2024 Category: Endocrinology Source Type: research
Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer
Breast cancer is the most prevalent malignant tumor among women, with hormone receptor-positive cases constituting 70%. Fulvestrant, an antagonist for these receptors, is utilized for advanced metastatic hormo... (Source: Journal of Nanobiotechnology)
Source: Journal of Nanobiotechnology - March 12, 2024 Category: Nanotechnology Authors: Li Zhi, Chen Cheng, Luo Jing, Peng Zhi-Ping, Yang Lu, Tian Yan, Wang Zhi-Gang and Yin Guo-Bing Tags: Research Source Type: research
Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor ‐positive, HER2‐negative metastatic breast cancer: A real‐world multicenter study
ConclusionThis study provided real-world data for the use of chidamide in patients with HoR-positive and HER2-negative MBC. Our data endorsed the use of chidamide in patients pretreated with CDK4/6 inhibitors and patients treated with different endocrine combinations. (Source: Cancer Medicine)
Source: Cancer Medicine - March 8, 2024 Category: Cancer & Oncology Authors: Doudou Li,
Yizi Jin,
Mingxi Lin,
Cheng Zeng,
Qing Guo,
Yanfei Liu,
Jian Zhang Tags: RESEARCH ARTICLE Source Type: research
Mammalian enabled protein enhances tamoxifen sensitivity of the hormone receptor-positive breast cancer patients by suppressing the AKT signaling pathway
CONCLUSIONS: This study demonstrated that downregulation of MENA promoted tamoxifen resistance in the HR+ breast cancer tissues and cells by enhancing the AKT signaling pathway. Therefore, MENA is a promising prediction biomarker for determining tamoxifen sensitivity in patients with HR+ breast cancer.PMID:38459605 | DOI:10.1186/s13062-024-00464-3 (Source: Cancer Control)
Source: Cancer Control - March 8, 2024 Category: Cancer & Oncology Authors: Lifang He Chuanghong She Sen Jiang Zhaochang Qi Zihao Deng Likeng Ji Yukun Cui Jundong Wu Source Type: research
Real-world Data on Safety Outcome with Treatment of Adjuvant Abemaciclib plus Endocrine Therapy in High-risk Early Hormone-positive, HER2-negative Breast Cancer Patients
Purpose: Adjuvant abemaciclib plus endocrine therapy was approved for high-risk early breast cancer patients within the NHS in June 2022, based on the phase III study Monarch E trial demonstrating improved invasive disease-free survival and an acceptable safety profile compared with endocrine therapy alone [1,2]. The aim of our study was to assess the adverse event profile and tolerability of adjuvant abemaciclib/endocrine therapy in real-world clinical practice in comparison to the trial. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: H. Neralla, K. Herring, A. Stevens, D. Rea, L. Pallan Source Type: research
The Prognostic Value of Low HER2 Expression on Treatment Outcomes in Metastatic Hormone Receptor-positive Breast Cancer Patients Treated with CDK4/6 Inhibitors and Endocrine Therapy
Purpose: The combination of CDK4/6 inhibitors (CDK4/6i) with endocrine treatment (ET) has significantly improved treatment outcomes in metastatic hormone receptor-positive (HR+) breast cancer (BC) patients. Limited evidence exists regarding the effectiveness of CDK4/6i in HER2-low BC that recently identified as a targetable subtype of breast tumours [1]. This observational study aimed to investigate the impact of low HER2 expression on patient outcomes. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: R. Muhammad, S. Mumtaz, N. Goyal, A. Konstantis Source Type: research
Relapsing eosinophilic pneumonia in a patient with recurrent breast cancer receiving abemaciclib plus endocrine therapy
This report presents the case of a 42-year-old Japanese woman with recurrent hormone receptor –positive breast cancer who developed eosinophilic pneumonia (EP) during treatment with abemaciclib combined with endocrine therapy. Seven years after a radical surgery and definite diagnosis of Stage I breast cancer, her cancer recurred with metastases to multiple organs. Initially treated with a bemaciclib plus letrozole and goserelin for 3 months, she developed EP, which improved after the discontinuation of anti-cancer treatment and the administration of prednisolone. However, EP occurred again upon the reintroduction of end...
Source: Respirology Case Reports - March 7, 2024 Category: Respiratory Medicine Authors: Hiroaki Ogata,
Chinami Koga,
Toyoshi Yanagihara,
Yuki Moriuchi,
Aimi Enokizu ‐Ogawa,
Akiko Ishimatsu,
Junji Otsuka,
Kazuhito Taguchi,
Atsushi Moriwaki,
Eriko Tokunaga,
Makoto Yoshida Tags: CASE REPORT Source Type: research
Cancers, Vol. 16, Pages 1083: Characteristics of Cancer Stem Cells and Their Potential Role in Endometrial Cancer
i
Endometrial cancer is one of most common types of gynaecological tumours in developing countries. It has been suggested that cancer stem cells play an important role in the development of endometrial cancer. These are a subset of highly tumorigenic cells with similar features to normal stem cells (unlimited proliferation, multi-potential differentiation, self-renewal, aggressiveness, invasion, recurrence, and chemo- and endocrine therapy resistance). Wnt/β-catenin, Hedghog, and Notch1 are the most frequently activated pathways in endometrial cancer stem cells. The presence of cancer stem cells is associa...
Source: Cancers - March 7, 2024 Category: Cancer & Oncology Authors: Karolina Fr ąszczak Bart łomiej Barczyński Tags: Review Source Type: research
Differences in Preferences for Drug Therapy Between Patients with Metastatic Versus Early-Stage Breast Cancer: A Systematic Literature Review
ConclusionsRegardless of the stage, patients with BC consistently valued survival gains as the most important attribute and were willing to accept the risk of potential ADRs. Incorporating patient preferences in shared decision making may improve the effectiveness of interventions by enhancing adherence to drug therapy in patients suffering from BC. (Source: The Patient - Patient-Centered Outcomes Research)
Source: The Patient - Patient-Centered Outcomes Research - March 7, 2024 Category: International Medicine & Public Health Source Type: research
Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer
CONCLUSION: This study expands on previous findings by demonstrating that BCAR4 expression is associated with resistance to newer therapies. The identification of patients with intrinsic resistance to hormone therapy is crucial to avoid ineffective treatment strategies. These findings contribute to our understanding of endocrine therapy resistance in breast cancer and could potentially guide the development of more effective treatment strategies.PMID:38443227 | DOI:10.1016/j.clbc.2024.02.007 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 5, 2024 Category: Cancer & Oncology Authors: Muheng Liao Jace Webster Emily M Coonrod Katherine N Weilbaecher Christopher A Maher Nicole M White Source Type: research
